Specialised - Recombinant Factor VIII
key details
| Value | £70,000,000 |
|---|---|
| Status | cancelled |
| Category (CPV) | 33141530 |
| Contract start | 1 Jul 2020 |
| Contract end | 30 Jun 2021 |
| Procedure | open |
| SME suitable | Yes |
| OCID | ocds-b5fd17-cf2658d5-59df-4a39-a4bf-279ebb1a2173 |
description
Recombinant Factor VIII
notice history
1 notice published against this procurement.
| Published | Type | Regime | Notice |
|---|---|---|---|
| 4 Nov 2019 | Planning (planning) | · | 2d1c3a21-7282-4d63-b5f0-92bc699d44ea-323629 |
more from NHS ENGLAND
- Products for the treatment of Haemophilia A · £215,000,000 · 11 May 2023
- NHS Framework Agreement for the supply of products for the treatment of Haemophilia A · £215,000,000 · 26 Apr 2023
- NHS Framework Agreement for the Supply of Human Normal Immunoglobulin & Anti-D Immunoglobulin · £526,598,540 · 3 Feb 2023
- NHS Framework Agreement for the supply of Adult Influenza Vaccines - Secondary Care · £16,000,000 · 22 Jul 2022
- National Framework Agreement for the supply of products for the management of Hereditary Angioedema · £74,500,000 · 5 Jul 2022
- NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema · £74,500,000 · 5 Jul 2022
- NHA National Framework Agreement for the supply of products for the treatment of Bleeding Disorders including Haemophilia B · £250,000,000 · 5 Jul 2022
- NHS National Framework Agreement for the supply of products for the treatment of Haemophilia A · £214,000,000 · 22 Mar 2022
all contracts from this buyer →
similar contracts awarded
Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.
- Purchase of Diathermy · Leeds Teaching Hospitals NHS Trust · £48,000
- NHS Framework Agreement for the supply of Recombinant Factor IX products for the treatment of Haemophilia B · NHS England · £192,000,000
- Provision of R-Phycoerythrin F(ab)2-specific IgG antibody · Public Health England · £44,601
- National Framework Agreement for the supply of Recombinant Factor VIII products for the treatment of bleeding disorders · NHS England · £302,000,000
- HOME DELIVERY OF RECOMBINANT COAGULATION FACTORS FOR HAEMOPHILIA PATIENTS · University Hospitals of North Midlands NHS Trust
source
Published on Contracts Finder. Contact details for named individuals are not reproduced on this site.